Investigación sobre Hormonas
Secretagogos de GH, GH recombinante y gonadotropinas. A continuación se encuentra la literatura publicada para cada compuesto en esta área — 225 estudios en total, 84 de ellos publicados desde 2023, cada uno vinculado a su registro fuente.
- HormonasClínico temprano
CJC-1295
CJC-1295 se refiere a dos agonistas relacionados del receptor de la hormona liberadora de hormona de crecimiento (GHRH) derivados del fragmento N-terminal de 29 aminoácidos de la GHRH humana. La forma DAC lleva un enlazador de maleimidopropionilo que forma un complejo de afinidad farmacológica covalente con la albúmina circulante, extendiendo la vida media plasmática a aproximadamente una o dos semanas y produciendo una elevación sostenida de GH e IGF-1; la forma sin DAC, denominada con mayor precisión modified GRF(1-29), carece del enlazador y conserva únicamente las modificaciones de columna vertebral tetrasustituidas que resisten la escisión por dipeptidil peptidasa-IV, otorgando una duración de acción corta comparable a la de sermorelin. Los datos humanos se limitan a un pequeño número de estudios de fase I y fase II de la forma DAC realizados entre 2005 y 2009, que establecieron una elevación prolongada y dependiente de la dosis de GH e IGF-1 con pulsatilidad de GH preservada. No se localizó ningún ensayo controlado aleatorizado revisado por pares de la forma modified GRF(1-29) sin DAC, y la mayor parte de la literatura publicada desde 2019 se refiere a metodología de detección antidopaje o revisiones narrativas del uso de péptidos no aprobados en lugar de nuevos datos clínicos.
- Estudios
- 16
- Desde 2023
- 8
- Más reciente
- 2026
- HormonasClínico temprano
CJC-1295 + Ipamorelin
No se identificó ningún ensayo clínico revisado por pares que administrara CJC-1295 junto con ipamorelin; una búsqueda en PubMed que intersectaba ambos nombres de péptidos devolvió únicamente revisiones narrativas, métodos analíticos de control de dopaje y análisis de calidad de productos, sin ningún estudio intervencionista del par. La evidencia disponible es, por tanto, a nivel de componentes, comprendiendo estudios humanos aleatorizados de CJC-1295 (un análogo de GHRH de acción prolongada) y de ipamorelin (un agonista selectivo de GHS-R1a) evaluados por separado, junto con un cuerpo más antiguo de trabajo humano sobre la co-administración de GHRH con péptidos liberadores de hormona de crecimiento o grelina, que estableció que las dos vías de receptores interactúan más que aditivamente. La literatura reciente de 2024-2026 abordó esta combinación casi exclusivamente como un producto compuesto no aprobado utilizado fuera de la medicina regulada, y caracterizó su base de evidencia clínica como ausente en lugar de negativa.
- Estudios
- 15
- Desde 2023
- 5
- Más reciente
- 2026
- HormonasFármaco aprobado
HCG
Human chorionic gonadotropin is a heterodimeric placental glycoprotein hormone that shares an alpha subunit with LH, FSH and TSH and signals through the luteinizing hormone/chorionic gonadotropin receptor (LHCGR), reproducing LH activity with a substantially longer circulating half-life. Urinary-derived hCG and recombinant choriogonadotropin alfa are approved agents used to trigger final oocyte maturation and ovulation in assisted reproduction, to support Leydig-cell testosterone production and induce or maintain spermatogenesis in male hypogonadotropic hypogonadism, and historically as hormonal therapy for undescended testis. Serum hCG measurement is also a core diagnostic assay in pregnancy monitoring and in gestational trophoblastic disease. The evidence base is large and dominated by randomised trials and their syntheses, so recent systematic reviews, network meta-analyses and Cochrane reviews carry most of the weight; controlled evidence does not support hCG as a weight-loss agent.
- Estudios
- 40
- Desde 2023
- 15
- Más reciente
- 2026
- HormonasFármaco aprobado
HMG
Human menopausal gonadotropin (menotropins) is a urinary-derived gonadotropin preparation containing both follicle-stimulating hormone and luteinizing hormone activity, the latter contributed substantially by chorionic gonadotropin retained during purification. Highly purified formulations (hp-hMG) have been evaluated against recombinant FSH and against rFSH plus recombinant LH in a large randomised-controlled-trial literature covering ovarian stimulation for IVF/ICSI, ovulation induction, and combined gonadotropin therapy for spermatogenesis induction in male hypogonadotropic hypogonadism. A 2026 Cochrane update reported probable advantages for hMG/hp-hMG over rFSH in live birth and ovarian hyperstimulation syndrome, while other recent systematic reviews found comparable live birth with differing oocyte yields, and the field remains characterised by heterogeneity in dosing, protocol and endpoint definition.
- Estudios
- 37
- Desde 2023
- 16
- Más reciente
- 2026
- HormonasSolo preclínico
IGF-1 LR3
Long R3 IGF-I (LR3-IGF-I) is a recombinant analogue of human IGF-I with a 13-amino-acid N-terminal extension and arginine in place of glutamate at position 3, developed in Adelaide in the early 1990s. These changes sharply reduced binding to IGF-binding proteins, and in cell and rodent studies the analogue was several-fold more potent than native IGF-I for anabolic and gut-growth effects despite being cleared from plasma more rapidly. In pigs and marmosets it produced stronger and longer-lasting hypoglycaemia than IGF-I, it suppressed growth hormone in pigs and monkeys, and it reduced growth in pigs. Recent animal studies reported no cognitive benefit in an Alzheimer's mouse model and no growth benefit in growth-restricted fetal sheep. No human studies have been published, and anti-doping laboratories have identified research-grade and degraded forms in black-market products.
- Estudios
- 15
- Desde 2023
- 4
- Más reciente
- 2026
- HormonasClínico temprano
Ipamorelin
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts as a selective agonist at the growth hormone secretagogue receptor 1a (GHS-R1a, the ghrelin receptor). It was first characterised in 1998 as the first secretagogue in its class to release growth hormone with potency comparable to GHRP-6 while not significantly elevating ACTH or cortisol above levels seen after GHRH stimulation. Preclinical work has examined longitudinal bone growth, bone mineral content, gastrointestinal motility, nociception and cisplatin-induced weight loss, and human pharmacokinetic-pharmacodynamic modelling has been published. Clinical development advanced to a randomised placebo-controlled phase 2 trial in postoperative ileus after bowel resection, which did not meet its primary endpoint; recent literature consists largely of narrative reviews on unapproved performance-enhancing and therapeutic peptides.
- Estudios
- 18
- Desde 2023
- 9
- Más reciente
- 2026
- HormonasClínico temprano
Kisspeptin-10
Kisspeptin-10 (KP-10) is the C-terminal decapeptide fragment of the KISS1 gene product and an agonist at the kisspeptin receptor KISS1R (GPR54). Loss-of-function mutations in KISS1R were shown in 2003 to cause normosmic hypogonadotropic hypogonadism, establishing kisspeptin signalling as an upstream regulator of gonadotropin-releasing hormone secretion. Human administration studies, largely conducted at Imperial College London, have examined intravenous, subcutaneous and intranasal kisspeptin and its longer isoform kisspeptin-54 in healthy volunteers and in reproductive disorders. Kisspeptin is an investigational agent; no kisspeptin peptide is approved as a medicine in any major jurisdiction.
- Estudios
- 42
- Desde 2023
- 14
- Más reciente
- 2026
- HormonasFármaco aprobado
Somatropin
Somatropin is a 191-amino-acid recombinant form of human growth hormone that acts through the growth hormone receptor and the downstream JAK/STAT pathway, largely via hepatic and local induction of insulin-like growth factor 1 (IGF-1). It has been an approved therapeutic since the mid-1980s and carries one of the larger clinical evidence bases in endocrinology, spanning childhood and adult growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age short stature and idiopathic short stature. The contemporary literature is dominated by systematic reviews, network meta-analyses and consensus statements, with a recent centre of gravity on long-acting weekly analogues (somapacitan, somatrogon, lonapegsomatropin, pegylated formulations) benchmarked against daily somatropin. Long-term registry and cohort surveillance has focused on mortality, malignancy incidence and metabolic outcomes.
- Estudios
- 42
- Desde 2023
- 13
- Más reciente
- 2026
Investigación publicada más reciente
Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry
Journal of Pharmaceutical and Biomedical Analysis · CJC-1295 como analito; orina humana, desarrollo de método analítico
PubMed · 41138283Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications
JBJS Reviews · CJC-1295 dentro de la clase de secretagogos de GH; revisión narrativa estructurada de literatura 2020-2025
PubMed · 42160466Peptide Supplements and Their Therapeutic Applications in Sports Medicine
The American Journal of Sports Medicine · CJC-1295 (forma no distinguida consistentemente); revisión exploratoria de seis péptidos
PubMed · 42578445Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Sports Medicine · CJC-1295 entre péptidos no aprobados; revisión narrativa
PubMed · 41966639The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Frontiers in Endocrinology · CJC-1295 con y sin DAC; revisión narrativa de péptidos del eje GH-IGF1
PubMed · 42395176Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
International Journal of Molecular Sciences · CJC-1295 entre péptidos endócrino-activos; revisión de literatura de 106 artículos
PubMed · 42123471Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
JBJS Rev · Revisión narrativa estructurada de péptidos inyectables
PubMed · 42160466Real-world diagnostic performance of the macimorelin stimulation test in the diagnosis of adult growth hormone deficiency.
Pituitary · Cohorte clínica del mundo real sometida a pruebas de estimulación de GH
PubMed · 41793495
Solo para fines de investigación. No apto para consumo humano, diagnóstico, tratamiento o prevención de ninguna condición. Nada en esta página constituye consejo médico.